Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

411P - Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

Date

21 Oct 2023

Session

Poster session 03

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Frederik Marmé

Citation

Annals of Oncology (2023) 34 (suppl_2): S334-S390. 10.1016/S0923-7534(23)01260-7

Authors

F. Marmé1, C. Brucker2, T. Decker3, P. Fasching4, T. Göhler5, C. Jackisch6, J. Janssen7, A. Koehler8, K. Luedtke-Heckenkamp9, D. lüftner10, M. Van Mackelenbergh11, A. Nusch12, B. Rautenberg13, M. Schmidt14, T. Reimer15, R. Weide16, P. Wimberger17, S. Maslanka Figueroa18, C. Roos18, A. Woeckel19

Author affiliations

  • 1 Gynecologic Oncology Department, Med. Fakultät Mannheim der Universität Heidelberg, 68167 - Mannheim/DE
  • 2 Klinikum Nürnberg Nord, Paracelsus Medical University, 90471 - Nurnberg/DE
  • 3 Oncology Ravensburg, Oncology Ravensburg, 88212 - Ravensburg/DE
  • 4 Department Of Obstetrics And Gynecology, University Hospital Erlangen, 91054 - Erlangen/DE
  • 5 Onkozentrum Dresden/freiberg, Onkozentrum Dresden/Freiberg, 01127 - Dresden/DE
  • 6 Department Of Obstetrics And Gynecology, Sana Klinikum Offenbach, 63069 - Offenbach am Main/DE
  • 7 Medizinische Studiengesellschaft Nord-west Gmbh, Medizinische Studiengesellschaft Nord-West GmbH, 26655 - Westerstede/DE
  • 8 Practice For Hematology And Oncology, Practice for Hematology and Oncology, 63225 - Langen (Hessen)/DE
  • 9 Department Of Oncology And Hematology, Niels-Stensen-Kliniken, 49124 - Georgsmarienhütte/DE
  • 10 Department Of Hematology, Oncology And Tumor Immunology, Charité University Hospital, 14770 - Berlin/DE
  • 11 Gynecology Breast Unit, Universitätsklinikum Schleswig-Holstein, 24105 - Kiel/DE
  • 12 Practice For Hematology And Medical Oncology Velbert, Practice for Hematology and Medical Oncology Velbert, 42551 - Velbert/DE
  • 13 Universitätsklinik Für Frauenheilkunde, Universitätsklinikum Freiburg, 79106 - Freiburg im Breisgau/DE
  • 14 Klinik Und Poliklinik Für Geburtshilfe Und Frauengesundheit, Universität Mainz, 55131 - Mainz/DE
  • 15 University Hospital Rostock, University Hospital Rostock, 18059 - Rostock/DE
  • 16 Invo Gbr, InVO GbR, 56068 - Koblenz/DE
  • 17 Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, 01307 - Dresden/DE
  • 18 Medical Department, Novartis Pharma GmbH, 90429 - Nürnberg/DE
  • 19 Department Of Obstetrics And Gynecology, University Hospital Würzburg, 97080 - Wuerzburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 411P

Background

RIBANNA (CLEE011ADE03) is a prospective, noninterventional study assessing the efficacy and safety of RIB+AI/FUL, endocrine therapy (ET) alone, or chemotherapy (CT) in 1L and subsequent therapy lines in pre-, peri- and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer. Herein we present real-world data on therapy management for RIB, including therapy-related adverse events (AEs), dose adjustment, and efficacy outcomes in special subgroups resulting from the 5th IA from RIBANNA.

Methods

Pre-, peri- and postmenopausal patients within the study were treated according to German treatment guidelines. For the RIB cohort the number of dose adjustments, reason and time until dose adjustment and/or discontinuation will be presented. Effectiveness analysis for PFS in 1L will be performed for patients with and without dose adjustments. Safety analysis and the median time to toxicity will be explored, with focus on AEs of special interest (AESIs): liver toxicity, cardiac events and neutropenia.

Results

At data cutoff Sep 6, 2022, 2581 patients were enrolled in the study (RIB+AI/FUL, n = 2163; ET, n = 237; CT, n = 181). The mean RIB exposure (standard deviation [SD]) in 1L was 597.7 [459.2] days with a mean daily dose of 280.7 [132.3] mg/day and 519.1 [117.4] mg/day including and excluding interruptions, respectively. The unadjusted KM estimate for median PFS was 32.2 months (95% CI, 29.3–34.8) in the RIB + AI/FUL cohort. Regarding the AESIs (all grade): an increased alanine- and aspartate-aminotransferase was recorded in 3.9% (78) and 3.8% (75) of patients, respectively. Similarly, 3.7% (73) of patients had a prolonged QT interval on the electrocardiogram. Neutropenia was documented for 25.8% (511) of the patients, being one of the most frequent treatment-emergent adverse events.

Conclusions

The RIBANNA study encompasses a diverse patient population receiving RIB therapy. Data on the 1L therapy management in real-world settings including dose adjustments, efficacy in special populations and safety will be presented at the conference.

Clinical trial identification

CLEE011ADE03.

Editorial acknowledgement

Legal entity responsible for the study

Novartis Pharma GmbH.

Funding

Novartis Pharma GmbH.

Disclosure

F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK/Tesaro, Clovis, Pfizer, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Novartis, Roche, Gilead/Immunomedics, EISAI, PharmaMar, GenomicHealth, Myriad, Seagen; Financial Interests, Institutional, Invited Speaker: Seagen, Daiichi Sankyo, GSK, AstraZeneca; Financial Interests, Institutional, Advisory Board: Roche, Immunicom; Financial Interests, Institutional, Local PI: Roche, Novartis, Eisai, MSD, Vaccibody, GSK; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Roche, Gilead/Immunomedics, German Breast Group, AGO Research GmbH; Financial Interests, Institutional, Funding: AstraZeneca, Lilly, Seagen. T. Decker: Financial Interests, Personal, Advisory Board: Novartis, IOMEDICO; Financial Interests, Personal, Invited Speaker: Novartis, Lilly. P. Fasching: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Hexal, Lilly, Pierre Fabre, Seagen, Agendia, Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Lilly, Seagen, Gilead; Financial Interests, Personal, Other, Medical Writing Support: Roche; Financial Interests, Institutional, Local PI: BionTech, Cepheid; Non-Financial Interests, Member: ASCO, Arbeitsgemeinschaft für Gynäkologische Onkologie e.V., Translational Research in Oncology, Deutsche Gesellschaft für Senologie e.v.. C. Jackisch: Financial Interests, Personal, Invited Speaker: Roche, Exact Sciences, Gilead, Molecular Health; Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Daiichi Sankyo, Pfizer. J. Janssen: Financial Interests, Personal, Advisory Board: AstraZeneca, Eigene, BMS, Ibsen, Johnson & Johnson, Janssen Oncology, Lilly, Novartis, Roche; Financial Interests, Institutional, Local PI: AstraZeneca, Eigene, BMS, Ibsen, Johnson , Janssen , Lilly, Novartis, Roche. A. Koehler: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Amgen, Daiichi Sankyo, MSD. K. Luedtke-Heckenkamp: Financial Interests, Personal, Advisory Board: Roche, Daiichi Sankyo, Lilly; Financial Interests, Personal, Invited Speaker: Novartis, Gilead, Pfizer, AstraZeneca; Financial Interests, Institutional, Local PI: Roche, Gilead, Daiichi Sankyo, Novartis, Pfizer, Seagen. D. lüftner: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Pfizer, Daiichi Sankyo, Onkowissen, GSK; Financial Interests, Personal, Invited Speaker: Eli Lilly, Novartis, High5md, Loreal; Financial Interests, Institutional, Funding: Novartis. M. Van Mackelenbergh: Financial Interests, Personal, Other, Personal Fees, Honoraria or Travel grants: Amgen, AstraZeneca, Daiichi Sankyo, Genomic Health, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, PierreFabre, Roche, Seagen. B. Rautenberg: Financial Interests, Personal, Advisory Board, Honoraria, congress/travel grants: Novartis, Roche, Daiichi Sankyo, Lilly, MSD. M. Schmidt: Financial Interests, Personal, Advisory Board: AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Roche, SeaGen; Financial Interests, Institutional, Local PI: AstraZeneca, Roche, Novartis, Pierre Fabre; Financial Interests, Personal, Trial Chair: Pfizer. T. Reimer: Financial Interests, Personal, Invited Speaker: Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Roche; Financial Interests, Personal, Advisory Board: Pfizer. R. Weide: Financial Interests, Institutional, Funding: Amgen, Biotest, Celgene, CSL Behring, Daiichi Sankyo, Eisai, GSK, Hexal, Lilly, Medac, Mundipharma, Octapharma, Takeda. P. Wimberger: Financial Interests, Personal, Invited Speaker: AstraZeneca, Lilly GmbH, Roche GmbH, MSD, EISAI, GSK, GILEAD, Pfizer, Novartis. S. Maslanka Figueroa: Financial Interests, Personal, Full or part-time Employment: Novartis. C. Roos: Financial Interests, Personal, Full or part-time Employment: Novartis Pharma GmbH. A. Woeckel: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Pfizer, Roche, MSD; Financial Interests, Personal, Invited Speaker: Lilly, Novartis, Pfizer, Gilead, Daiichi Sanko. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.